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model for policy and planning
Key Messages
1. The largest contribution of 
coronary heart disease (CHD) 
mortality reductions was from 
medical treatment.
2. A smaller contribution was 
estimated to be due to risk 
factors changes.
3. Improvement of treatment 
uptake levels can have a 
substantial effect in reducing 
CHD mortality.
Hong Kong Med J 2009;15(Suppl 2):S22-5
Introduction
Coronary heart disease (CHD) is the most common cause of death in developed 
countries. The death rate due to CHD is increasing in most developing countries 
and is projected to become the leading cause of death in 2020 with over 7 million 
deaths each year. In Hong Kong, heart disease was the second highest cause of 
mortality in 2005 (after cancer) and accounted for about 10% of all deaths. In 
2005, the crude death rate due to CHD in Hong Kong was approximately 60 per 
100 000 inhabitants. Although this CHD mortality rate is lower than that in many 
western countries, it is still useful to examine the impact of therapies versus 
changes in risk factors on CHD mortality rates, in order to predict future trends.
	 Many	large	cohort	studies	have	already	identified	trends	in	CHD,	including	
the World Health Organization MONICA project and the Framingham study. 
However, in a number of countries including China, a further modelling approach 
using easily available data has been used to explain trends in terms of treatment 
or risk factor changes.1 We sought to apply this model to Hong Kong.
Aim
The aim of the impact model project was to relate recent CHD trends to treatments 
and changes in population risk factors.
Methods
This study was conducted from October 2005 to September 2006. A Microsoft 
Excel cell-based model was used to examine CHD mortality in Hong Kong 
between 1989 and 2001, as the best quality data were collected in these years. 
The impact model was originally created for the UK2 and has since been applied 
to many other countries. The main model used in Hong Kong was that developed 
for the US in 20053	but	with	modifications.	The	model	was	applied	to	males	and	
females aged 25 to 84 years only. The age-group of 85 years and older was not 
included because of limited data.
Medical and surgical treatments
Population and mortality data were obtained from the Hong Kong Census and 
Statistics Department and the Department of Health respectively. Numbers of 
discharges and deaths were obtained from the Hospital Authority clinical data. 
Treatment prescription rates and case fatality data were based initially on the 
UK model. Data on the relative risk of each treatment were obtained from 
published controlled trials and meta-analyses that were also used in previous 
impact models. The prevalence of hypertension, community angina and heart 
failure cases were based on local publications. Overall patient compliance and 
adjustments for potential overlap between CHD patient groups were based on the 
same assumptions as in previous impact models.
Risk factors
Changes in major risk factors may also have contributed to changes in mortality 
rates for CHD. The classical risk factors included in this model were blood 
pressure, cholesterol, body mass index, smoking and diabetes. Other factors 
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such as physical inactivity were not included in this model 
since there were no reliable data. Data on risk factor 
prevalence were obtained from three local studies: China 
Light and Power study in 1990, Cardiovascular Risk Factor 
Prevalence (CRFP) study in 1995-96 and Population Health 
Survey (PHS) in 2003/2004.
Mant and Hicks correction
Multiple medications could be taken by individual 
CHD patients. However, the mortality reduction due to 
polypharmacy is unlikely to be simply the additive effect 
of each separate treatment. The cumulative effect was 
estimated by using the Mant and Hicks approach and 
separate	relative	risk	reductions	(RRRs)	where:	benefit	=	
1 - [(1 – RRR from treatment A) * (1 – RRR from treatment 
B) * … etc].
Sensitivity analysis
Sensitivity analysis was performed for each main assumption 
and estimate included in the model, such as uptake level, 
case fatality, and relative risk. Assumptions about maximum 
and minimum values were based on the highest or lowest 
values that could be obtained from internationally published 
studies. Otherwise, +/- 20% of the main parameters were 
used to generate the maximum or minimum possible for 
deaths prevented or postponed (DPP) for each treatment or 
risk factor.
Model validation
The number of DPP was estimated for each medication and 
cardiovascular	 risk	 in	between	1989	and	2001,	 stratified	
by gender and age. This number was compared with the 
actual change in CHD mortality in the period, where the 
actual change was calculated as the number of deaths 
attributed to CHD in 2001 if the mortality rate stayed at 
the 1989 level minus the number of observed CHD deaths 
in 2001.
Results
Between 1989 and 2001, the actual mortality rates for CHD 
in Hong Kong in persons aged 25 to 84 years decreased 
from 79 to 76 per 100 000 in men and from 60 to 42 per 
100 000 in women. The mortality rates were based on 3-year 
averages for the years 1988-90 and 2001-03 respectively. 
Using the population data and mortality rate in Hong Kong 
for 1989 and 2001, we estimate that there would have been 
3928 CHD deaths expected in 2001 if the 1989 mortality 
rates had persisted, but only 2742 deaths were observed in 
2001. Therefore 1186 CHD deaths (the actual fall) were 
prevented or postponed between 1989 and 2001.
Medical and surgical treatments
The model estimated that 1233 CHD deaths were prevented 
or postponed by medical and surgical treatments in 2001. 
After applying the Mant and Hicks correction and adjusting 
for treatments that were already used in 1989, there were 
928 deaths estimated to be prevented or postponed by 
treatment between 1989 and 2001 (Table 1). Treatments 
for initial acute myocardial infarction (AMI), secondary 
prevention post AMI, as well as heart failure, hypertension 
and hyperlipidaemia treatments have contributed to a 
larger proportion of the mortality reductions; respectively 
estimated as 195, 221, 164 and 249 CHD deaths. Smaller 
contributions to DPP were estimated from secondary 
prevention post angioplasty (44 deaths) and treatment for 
chronic angina (54 deaths).
Risk factors
The changes in cardiovascular risk factors did not contribute 
a great deal to CHD DPP in Hong Kong between 1989 and 
2001. Only 336 CHD deaths were prevented or postponed 
by changes in all major risk factors (Table 2). The largest 
contribution came from the decline in smoking prevalence, 
which prevented 328 CHD deaths. The decrease in mean 
Treatments Deaths prevented or postponed Minimum estimate Maximum estimate
Acute myocardial infarction (AMI) 320 191 522
Treatments in effect 1989 -125 -40 -244
Total secondary prevention
Secondary prevention after AMI 247 145 496
Treatments in effect 1989 -25 -8 -54
Secondary prevention after angioplasty 44 17 77
Chronic angina 
Unstable angina 10 7 18
Community angina 44 20 92
Heart failure
Hospital heart failure 164 87 325
Community heart failure 0 -5 13
Hypertension and hyperlipidaemia treatment
Hypertension 298 131 616
Treatments in effect in 1989 -155 -40 -401
Hyperlipidaemia 106 45 219
Total treatments 
2001 1233 637 2378
1989 -305 -88 -699
Treatments between 1989 and 2001 928 550 1678
Table 1. Deaths prevented or postponed by treatments in Hong Kong 1989-2001
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diastolic blood pressure in men avoided 213 CHD deaths, 
while 57 more deaths were produced due to the increase in 
blood pressure in women. As 143 deaths were prevented by 
hypertension treatments, the total CHD deaths prevented by 
population blood pressure changes therefore decreases to 
13 after adjustment. The decline in mean cholesterol levels 
resulted in 281 CHD DPP. However, 177 of these deaths 
were prevented by cholesterol treatments and only 104 by 
the change in cholesterol level. Decreased mean body mass 
index could have prevented 47 CHD deaths, 10 in men and 
37 in women. Diabetes prevalence was the only risk factor 
that resulted in an overall increase in deaths. Increased 
diabetes prevalence resulted in 156 more CHD deaths.
Validation
The model estimated that a total of 1264 deaths were 
prevented or postponed between 1989 and 2001 compared 
to 1186 fewer deaths in reality. Of these, 78% of the 
actual reduction was attributable to treatment and 28% to 
risk factor changes. The model overestimated the deaths 
prevented	 or	 postponed	 and	 the	 overall	 model	 fit	 with	
actual changes in mortality is 106%—143% for men and 
68% for women.
Sensitivity analyses
Sensitivity analyses showed that CHD deaths prevented or 
postponed were consistent among all medical treatments. 
The effects of all treatments together prevented 928 deaths, 
with a minimum of 550 and maximum 1678. All risk factor 
changes together prevented 336 deaths, with a minimum of 
125 and maximum 866. By all risk factors changes, DPP 
showed a greater contribution for the maximum estimation 
when compared to the best estimation, which showed that 
DPP by risk factors may be underestimated in the model.
Discussion
As the most westernised city in China, Hong Kong has 
experienced a rise in CHD mortality one to two decades 
earlier than the remainder of China. The mortality rate 
for CHD in Hong Kong was still increasing in the 1970s 
and peaked around 1980. Although the crude death rate 
has remained fairly stable, age-standardised mortality has 
dropped substantially over the past two decades. However, 
the trends in mortality reduction were not similar to those in 
western countries. Mortality due to CHD in Hong Kong has 
remained low despite rapid economic growth. The mortality 
rate is about half of that observed in the US and UK. The 
influences	of	changes	in	treatments	and	risk	factors	on	CHD	
mortality could therefore show a different effect.
Medical and surgical treatments
The advances in treatments have no doubt made a great 
contribution to preventing CHD mortality over the last 
20 years. Some of the therapies such as statins and aspirin 
are very cost-effective in primary and secondary care. 
New surgical treatments such as angioplasty also became 
available over this period. Although the effect of medical 
treatments may be overestimated in the model, a large 
proportion of DPP was estimated to result from advances in 
treatment. However treatment uptake rates may have been 
relatively low for some therapies, possibly due to the cost of 
implementation, patients dying before arriving at hospital 
or the treatment not being offered. A UK study showed that 
improvements in uptake could make a large impact on the 
reduction of CHD mortality, which suggested that DPP by 
current treatments would be double if the uptake levels 
increase to 80%.4 Thus, the effects of medical treatments in 
Hong Kong could be maximised if the future policies aim 
to improve treatment uptake of medications.
Risk factors
Only 28% of DPP was attributed to risk factor changes. 
The decline in smoking prevalence was attributed with the 
largest proportion of CHD mortality reduction among all 
the risk factors. A recent study proposed that the epidemic 
of tobacco in Hong Kong has entered an advanced period,5 
with cigarette consumption reaching a peak around 1970, 
20 years later than the US, and started to decline as also 
observed in US. The smoking trend in Hong Kong was 
thus predicted to be repeating the US trend but with a two 
decade delay.
 Mean diastolic blood pressures in Hong Kong have 
remained fairly stable between 1989 and 2001. However, 
mean systolic blood pressure was observed to increase 
in the same period, which is possibly due to ageing of 
the Hong Kong populations. Thus using diastolic blood 
pressure alone for calculating DPP may overestimate the 
real changes on mortality reduction by blood pressure.
Risk factors Deaths prevented or postponed Minimum estimate Maximum estimate
Blood pressure 156 133 182
Hypertension treatments -143 - -
Risk factors minus treatment 13 0 156
Smoking 328 206 563
Cholesterol level 281 239 401
Cholesterol treatments -177
Cholesterol diet only 104 0 281
Obesity 47 34 61
Diabetes -156 -115 -195
Risk factor total 336 125 866
Table 2. Deaths prevented or postponed by risk factors in Hong Kong 1989-2001
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 The dietary and fat intake pattern in the local Chinese 
population appeared to be close to the recommended level 
for cardiovascular health,6 suggesting unhealthy dietary 
patterns relating to fat consumption may not be a major 
determinant of CHD deaths. It is therefore unlikely that a 
large proportion of deaths from CHD could be prevented 
by a change of diet, at least when mediated through fat 
consumption. The estimated DPP associated with changes 
in mean cholesterol levels found over this period could 
be the effect of treatment. Therefore, it was assumed that 
the DPP due to change in cholesterol levels was mainly 
contributed by treatments and not lifestyle change.
 Mean body mass index (BMI) for Hong Kong women 
has declined substantially since 1989, while the BMI for men 
was similar in 1989 and 2003. The decline in female BMI 
may be due to social pressure for a lower ideal weight for 
women or a consequence of including a higher proportion of 
middle-aged women who are employed in the data from the 
CRFP and PHS study, where employed middle-aged women 
tended to have a lower BMI than those staying at home.
 Diabetes prevalence was the only risk factor that was 
observed to clearly increase over the study period. In the 
model, 156 CHD DPP were attributed to this change. The 
increase in diabetes among the Hong Kong population may 
be due to changes in lifestyle such as a decrease in physical 
activity.
 In comparison with other countries, the low mortality 
rate from CHD in Hong Kong seems to be consistent with 
most Asian countries, except Singapore (despite having 
a similar level of economic development). Singapore is 
the only country in Asia in which the CHD mortality rate 
has reached the level of western countries. The difference 
in serum cholesterol concentrations would explain the 
difference in CHD mortality and could be related to the 
high fat intake. The Beijing model also attributed the large 
increase in CHD deaths in mainland China to a rise in 
cholesterol levels. Change in diet and other lifestyle factors 
from traditional Chinese to mixed modern Chinese and 
western patterns seems to be the main issue in changes in 
CHD mortality rates. It is possible that Hong Kong may 
experience these changes in the future if western diets 
continue to be popular among the younger age-groups, 
as indicated by the prevalence of obesity in Hong Kong 
children and current dietary practices.
Limitations
The impact model is highly dependent on the quality of 
data available. Few comprehensive studies could be found 
for CHD treatments and risk factors in Hong Kong, data 
had to be estimated using the UK and Beijing models and 
assumptions made in those models. Adjustments were made 
when possible to tailor the data for Hong Kong. Risk factor 
trend data were very limited in Hong Kong. The smoking 
trend was the only risk factor with very reliable data. For 
the other risk factors, only three large cohort studies were 
considered good enough to use in the model. This limitation 
of the data sources impeded delineation of trends in risk 
factors. Sensitivity analysis showed that the mortality 
reduction attributed to risk factor changes may contribute 
a larger proportion, as the model may have underestimated 
the risk factor changes in Hong Kong between 1989 and 
2001 or possibly overestimated the DPP statistics due to 
medical treatment.
 The results appear to predict more than the actual number 
of deaths reduced. However, the overall pattern is similar 
to the Beijing model, with larger contributions to mortality 
reductions by all medical treatments and a relatively small 
contribution from risk factor changes. Unlike the Beijing 
model,	 the	Hong	Kong	model	did	not	find	an	 increase	 in	
deaths from risk factor changes. The Hong Kong model 
results fall between those for China and the US. Mortality 
due to CHD in Hong Kong is falling like that in the US, but 
locally the decline starts from a much lower peak mortality 
level.
Conclusions
Up to 78% of CHD mortality reduction between 1989 
and 2001 was attributed to improvements in treatment 
while 28% was attributed to changes in population risk 
factors.	The	findings	in	Hong	Kong	were	quite	different	to	
European studies, but similar to those observed in China. 
The CHD mortality rate in Hong Kong was already very 
low compared to western countries with similar levels 
of economic development. The model is consistent with 
improvements in treatment uptake and control of risk factors 
resulting in further CHD mortality reductions.
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